Narcolepsy without cataplexy

This study looks at the long-term safety and tolerability of the drug TAK-360 in people with narcolepsy (type 1 or 2) or idiopathic hypersomnia — conditions that cause severe daytime sleepiness. Participants who completed a previous TAK-360 study can join and will continue taking…

This study tests whether HBS-301 (pitolisant) can reduce excessive daytime sleepiness and cataplexy (sudden muscle weakness) in adults with narcolepsy. Participants receive either the drug or a placebo for several weeks, followed by an open-label phase where everyone gets the dru…

This study is a long-term follow-up for people with narcolepsy or idiopathic hypersomnia who previously took the experimental drug ORX750. Researchers want to see if the drug remains safe and effective over time. About 90 participants will take ORX750 orally and be monitored for …

This study is testing whether simple wearable devices can accurately screen for sleep disorders in children with cerebral palsy. About 140 children aged 6 to 15 will wear the devices at home and then undergo a standard hospital sleep test. The goal is to see if the wearable metho…

This study tests an experimental drug called cleminorexton in 222 adults with narcolepsy type 1 or 2. The drug mimics a natural brain protein that helps keep people awake. The goal is to see if it safely reduces daytime sleepiness and improves daily functioning. Participants must…

This study tests whether a special memory support program can help people aged 50 and older remember and stick to their sleep treatment. The program uses simple memory strategies alongside standard sleep therapy. Researchers will track sleep quality, daily functioning, and life s…

This study is testing the long-term safety and how well ALKS 2680 works over time in people with narcolepsy type 1, type 2, or idiopathic hypersomnia. Participants take a once-daily tablet at different doses. The goal is to see if the drug remains safe and effective for staying a…

This Phase 3 study tests whether expanded dosing regimens of Xywav can safely reduce excessive daytime sleepiness in adults with narcolepsy or idiopathic hypersomnia. About 108 participants will receive either Xywav or a placebo in a randomized withdrawal design. The main goal is…

This study tests a new drug called TAK-360 for people with narcolepsy type 2, a condition that causes severe daytime sleepiness. The drug acts like a natural brain chemical (orexin) that helps keep people awake. About 88 adults will receive either TAK-360 or a placebo to see if t…

This study tests a new tablet called ALKS 2680 to see if it can reduce daytime sleepiness in adults with narcolepsy type 2. About 176 participants will receive either the study drug or a placebo for 12 weeks. The main goal is to measure how well they can stay awake using a standa…

This study tests whether taking branched chain amino acids (BCAAs) twice a day for three weeks can improve sleep in people with traumatic brain injury. Researchers will also check if the supplement is easy to take and if participants stick with it. The study involves 300 veterans…

This study tests a drug called samelisant in 240 people with narcolepsy (with or without cataplexy). The goal is to see if it reduces excessive daytime sleepiness and sudden muscle weakness episodes over 12 weeks. Participants will take the drug or a placebo and report their slee…

This study follows 1,000 adults in Canada who are authorized to use medical cannabis for pain, sleep issues, anxiety, depression, or epilepsy. Researchers will track changes in symptoms using standard questionnaires over 24 weeks. The goal is to see how well medical cannabis work…

This study tests a non-medication therapy called Imagery Rehearsal Therapy to see if it can reduce nightmares in adults with narcolepsy. About 80 participants will receive the therapy and complete three assessments, with half starting right away and half later. The goal is to imp…

This study looks at whether adding sleep-focused treatments to standard psychiatric care can reduce suicide risk in young adults. About 90 college students with suicidal thoughts and sleep problems will be randomly assigned to one of three sleep interventions. Researchers will tr…

This study tests whether E2086, an oral tablet, can reduce excessive daytime sleepiness in adults with narcolepsy. About 64 participants will receive either the drug or a placebo for 4 weeks. Researchers will measure how long people can stay awake using a standard test, and also …

This study tests a new drug called ORX750 (cleminorexton) in 248 adults with narcolepsy type 1, type 2, or idiopathic hypersomnia—conditions that cause severe daytime sleepiness. The drug mimics a natural brain protein that helps keep people awake. The main goals are to check saf…

This study tests a 4-week online course designed to help adults who experience parasomnias—unwanted sleep events like sleep terrors, sleepwalking, and nightmares. The course teaches safety planning, relaxation, and therapy techniques. Researchers will measure whether it reduces h…

This study looks at how narcolepsy (types 1 and 2) and idiopathic hypersomnia affect social cognition—skills like recognizing emotions and making decisions. Researchers will give 75 adults several questionnaires to measure attention, impulse control, empathy, and emotion recognit…

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute…